Andain Inc. Discusses and Provides Update on Its Breakthrough Wrinkle Treating Nano-Particles Booster and Delivery for Regenerating Skin Tissue
Andain Inc. (OTCBB: ANDN) (“Andain” or the “Company”), a company engaged in commercializing novel technologies in biotech, medical and life sciences fields through its incubator program, today discussed and provided an update on its breakthrough, innovative peptide booster and delivery nano-particles for wrinkle treating and regenerating skin tissue collagen.
Andain has developed an intra-dermal nano-technology enhancing skin penetration of collagen cell stimulant peptides for cosmetic anti-wrinkle products.
The Company’s lipid-based nano-particles technology delivers generic peptides into the dermis skin layer, providing efficient and safe transport of peptides through the epidermis without physical or chemical changes in the skin barrier properties. Andain’s nano-particle technology provides effective protection of peptides from degradation by skin enzymes. With the designed controlled and timed release mechanism of the peptides at the dermis, this technology provides a prolonged and sustained treatment with no change or alteration of the skin properties. The nano-particles technology transfers and delivers the active-agent peptide payload through the epidermis to the dermis, preventing any amino acids attack on the payload and a controlled mechanism releases the active agent payload directly to the dermis collagen generating cells.
The Company’s intra-dermal delivery technology results in a safe way to deliver generic collagen generating boosters to the skin. The nano-particles shield the peptide from enzyme reaction all the way from the skin surface, through all the skin layers to the dermis. These shilling properties provide outstanding delivery properties, reducing the needed peptide quantity to 1/8 – 1/10 from normal peptide dosage use. Treatment increases by the adhesives properties to the collagen generating skin cells and timely peptides release a mechanism for prolonged treatment.
Andain’s President and CEO,
ABOUT ANDAIN INC
Established in 2004 as a
FORWARD LOOKING STATEMENTS
Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications that may arise could prevent the prompt implementation of any strategically significant plan(s) outlined above. The company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the company’s Form 10-K filing and other filings with the U S. Securities and Exchange Commission (available at http://www.sec.gov/). The company undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events, or otherwise.
American Capital Ventures
SOURCE Andain Inc